Deferasirox [90mg and 180mg Film Coated Tablet] for management of chronic iron overload due to repetitive blood transfusions in patients 2 years old and above
Minor Inclusion | DrugsHTA Council Recommendation (as of 12 January 2023)
As final recommendation, the HTA Council recommends the inclusion of deferasirox [90mg and 180mg film coated tablet] for management of chronic iron overload due to repetitive blood transfusions in patients 2 years old and above in the Philippine National Formulary (PNF).
Relevant Information
- Status: With Final HTA Council Recommendation and SOH Decision
- Topic Assignment: Internal Assessment
- Policy Question: Should deferasirox [90mg and 180mg Film Coated Tablet] for management of chronic iron overload due to repetitive blood transfusions in patients 2 years old and above be included in the Philippine National Formulary?
- Secretary of Health Decision: Approved on 01 February 2023
Evidence and Relevant Documents